Editorial: Fools rush in where angels fear to tread by Pearse, R.M.
The page number in the footer is not for bibliographic referencingwww.tandfonline.com/ojaa 3
 Editorial
Fools rush in where angels fear to tread
Despite advances in medical therapies, surgery remains a key 
component of the treatment for many diseases. Each year, more than 
300 million surgical procedures are performed worldwide, even though 
much of the global population is unable to access surgical treatments.1,2 
As the Lancet Commission on Global Surgery gains traction, we will see a 
substantial increase in the number of surgical procedures performed in 
low and middle income countries.3,4  This improvement is undoubtedly 
welcome, yet as anaesthetists we can expect significant new challenges 
to result. In 2018, a seminal work by the African Surgical Outcomes 
Study group transformed our understanding of postoperative outcomes 
in African countries.5 We now know that surgical patients in Africa are 
twice as likely to die after surgery even though they are younger, fitter 
and develop fewer complications. The new challenge is ‘failure to rescue’ 
or the undetected physiological deterioration of patients on the ward 
after surgery. As we succeed in extending access to surgical treatments 
in Africa, we must expect the absolute number of postoperative deaths 
to rise. The benefits of access to surgery cannot be fully realised unless 
these treatments are safe. In high income countries, this problem has 
been well described and tackled through various measures from staff 
education to support teams such as critical care outreach.6 Similar 
strategies can and will allow us to resolve this problem in Africa, but 
research is urgently needed to determine the best approach for a 
resource poor context.
In this edition of the Southern African Journal of Anaesthesia and 
Analgesia, we report the results of the ASOS-2 Pilot Trial.7 This was a 
pragmatic, international pilot study of 786 patients in 16 hospitals 
across eight African countries. Completing a pilot study of this size and 
complexity is itself a significant milestone for the group. Our aim was to 
test a new approach to preventing postoperative deaths through better 
postoperative surveillance. In particular, we wanted to understand the 
fidelity of the trial intervention (i.e. treatment compliance), the feasibility 
of the day to day trial tasks, and whether we were collecting all the data 
we needed. The main ASOS-2 trial will have a cluster randomised design 
which means entire hospitals will be allocated to the intervention or 
control groups. In the pilot, we only studied the proposed intervention 
arm of the trial as this is where the challenges in trial delivery will lie. 
Patients were risk stratified using the ASOS Surgical Risk Calculator,8 and 
those at high risk of severe complications or death were allocated to a 
bundle of additional care to ensure increased postoperative surveillance. 
The four interventions, selected on the basis of simplicity and low 
cost, were admission to a higher care ward, more frequent vital signs 
monitoring by nursing staff, location in a bed visible from the nursing 
station, and allowing family members to remain with the patient whilst 
in hospital. Our findings suggest it is possible to achieve substantial 
improvements in postoperative surveillance, although we will need 
to improve intervention compliance in the main trial. In some cases, 
barriers such as poorly located nursing stations, will be impossible to 
solve. By recognising this early, we will be able to adjust the intervention 
to reduce the impact of these problems and improve the chances of 
reducing mortality.
The purpose of clinical effectiveness (or pragmatic) trials is to confirm 
the benefits of a treatment which has shown promise in smaller efficacy 
(or explanatory) trials in the ‘real world’ clinical environment. Explanatory 
trials are designed to answer the question ‘can this treatment work?’, 
whilst pragmatic trials answer the question ‘does this treatment work?’ 
and typically include widely generalisable populations in a large number 
of hospitals. It is very important that we don’t progress to large pragmatic 
trials until we have a sound biological basis for our treatment strategy, in 
terms of dose, timing and patient population. In the context of ASOS-2, 
the pilot trial provides that explanatory learning which confirms a larger 
trial is worthwhile, and guides how this should be designed and run. 
Most readers will recognise the urgency to improve standards of care for 
patients in Africa. Some might cut corners with good scientific method 
to deliver a large trial quickly, but poor research will not help. The people 
of Africa deserve the highest standards of scientific rigour in the research 
which defines their healthcare. It is tempting to rush to perform what we 
hope will be a definitive major trial, but poorly designed trials may give 
incorrect answers to vital questions. Only with thoughtful pilot trials 
can we avoid this. The ASOS-2 Pilot Trial suggests that the proposed 
ASOS-2 Trial is both appropriate and feasible for Africa.7 I look forward 
to working with the ASOS-2 group to deliver what we all hope will be 
learning which saves many lives.
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